| | |
| Clinical data | |
|---|---|
| Trade names | Badyket, Ivor, Hibor, Zibor, others |
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | Subcutaneous injection (except for haemodialysis) |
| ATC code | |
| Pharmacokinetic data | |
| Bioavailability | 96% (estimated) |
| Elimination half-life | 5–6 hours |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| Chemical and physical data | |
| Molar mass | 3600g/mol (average) |
| | |
Bemiparin (trade names Ivor and Zibor, among others) is an antithrombotic and belongs to the group of low molecular weight heparins (LMWH). [1]
Bemiparin is used for the prevention of thromboembolism after surgery, and to prevent blood clotting in the extracorporeal circuit in haemodialysis. [2]
The medication is contraindicated in patients with a history of heparin-induced thrombocytopenia with or without disseminated intravascular coagulation; acute bleeding or risk of bleeding; injury or surgery of the central nervous system, eyes or ears; severe liver or pancreas impairment; and acute or subacute bacterial endocarditis. [2]
No interaction studies have been conducted. Drugs that are expected to increase the risk of bleeding in combination with bemiparin include other anticoagulants, aspirin and other NSAIDs, antiplatelet drugs, and corticosteroids. [2]
Like semuloparin, bemiparin is classified as an ultra-LMWH because of its low molecular mass of 3600 g/mol on average. [3] (Enoxaparin has 4500 g/mol.) These heparins have lower anti-thrombin activity than classical LMWHs and act mainly on factor Xa, reducing the risk of bleeding. [4]